LinkedIn Post by 89bio on September 18, 2025

Today we entered into a merger agreement to be acquired by @Roche. At the closing of the proposed transaction, 89bio and its employees will join the Roche Group and advance our innovative FGF21 analog, pegozafermin, as part of Roche’s Pharmaceuticals Division. Details here: https://ir.89bio.com/news-releases/news-release-details/89bio-inc-announces-agreement-be-acquired-roche